Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial

Thumbnail
Name:
Publisher version
Authors
Maisel, Alan
Mueller, Christian
Nowak, Richard M
Peacock, W. Frank
Ponikowski, Piotr
Mockel, Martin
Hogan, Christopher
Wu, Alan H.B.
Richards, Mark
Clopton, Paul
Affiliation
VA San Diego Healthcare System
San Diego Veterans Affairs Medical Center
University Hospital Basel
Henry Ford Health System
The Cleveland Clinic
Charité Medical School
Virginia Commonwealth University
University of California
University of Otago
Athens University Hospital Attikon
Issue Date
2011-08-30
Subjects
midregion proadrenomedullin
MR-proADM
shortness of breath

Metadata
Show full item record
Abstract
The aim of this study was to determine the prognostic utility of midregion proadrenomedullin (MR-proADM) in all patients, cardiac and noncardiac, presenting with acute shortness of breath.
Citation
Maisel, A. et al (2011) 'Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial' J. Am. Coll. Cardiol. 58 (10):1057-67
Publisher
American College of Cardiology
Journal
Journal of the American College of Cardiology
URI
http://hdl.handle.net/10547/593474
DOI
10.1016/j.jacc.2011.06.006
PubMed ID
21867843
Additional Links
https://www.jacc.org/doi/10.1016/j.jacc.2011.06.006
Type
Article
Language
en
ISSN
1558-3597
Collections